HGPII conducts industry review on GPOs
The Healthcare Group Purchasing Industry Initiative (HGPII; Washington) released its seventh annual Report to the Public, a comprehensive industry review which found that group purchasing organizations (GPOs) consistently maintain high ethical standards and business practices that promote innovation, transparency in the bidding process and compliance.
"Financial pressure on U.S. hospitals and healthcare providers has never been more acute, and providers rely on GPOs to reduce costs in all areas of the healthcare supply chain. HGPII is dedicated exclusively to the promotion of increased transparency and ethics in GPO business practices," said HGPII Co-Coordinator and former Representative Phil English. "After a year of conducting the most thorough interviews and site visits in HGPII's history, and reviewing responses to hundreds of questions, we have determined that HGPII members have created internal business safeguards and enforcement mechanisms to prevent conflicts of interest; improved transparency in the bidding and awards process; and developed and implemented policies that facilitate and promote the availability of news, innovative technologies for healthcare."
HGPII is a voluntary organization that was founded in a non-profit organization by the chief executives of those healthcare GPOs who thought the industry should do more collectively to demonstrate a strong commitment to ethical values. HGPII promotes the development and improvement of accountability standards, business practices, and ethics to its customers, vendors, and the public to help create higher industry standards for quality and value.
Carmenta reports preeclampsia data
Carmenta Bioscience (Palo Alto, California) in collaboration with researchers at Stanford University (Palo Alto, California) reported the presentation of results from a retrospective clinical study at the 2013 Society of Maternal Fetal Medicine national meeting. The presentation revealed a new confirmatory diagnostic test highly accurate in distinguishing mothers with preeclampsia from a control group in the study.
The underlying technology for the test was discovered by Carmenta's co-founders, Atul Butte, MD, and Bruce Ling, MD, of Stanford. Butte and Ling analyzed genomic and proteomic data from over 100 preeclamptic mothers to develop a novel, proprietary panel of serum proteins capable of diagnosis. Using advanced data mining techniques, they identified a multiplexed panel of biomarkers representing the broad diversity of biological processes associated with the condition.
Carmenta Bioscience is a privately held, medical technology company focused on advancing maternal and fetal health by applying a systems biology approach to the diagnosis and prediction of preeclampsia.